Gadolinium-Associated Plaques: A New, Distinctive Clinical Entity
IMPORTANCE: A new condition, gadolinium-associated plaques (GAP), is reported in 2 patients. It is related to a particular type of gadolinium (gadodiamide) used for contrast-enhanced radiologic studies. OBSERVATIONS: Erythematous plaques, 0.5 to 2.5 cm in diameter, were pruritic in one case and asym...
Gespeichert in:
| Veröffentlicht in: | JAMA dermatology (Chicago, Ill.) Ill.), 2015-03, Vol.151 (3), p.316-319 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 319 |
|---|---|
| container_issue | 3 |
| container_start_page | 316 |
| container_title | JAMA dermatology (Chicago, Ill.) |
| container_volume | 151 |
| creator | Gathings, Robert M Reddy, Raveena Santa Cruz, Daniel Brodell, Robert T |
| description | IMPORTANCE: A new condition, gadolinium-associated plaques (GAP), is reported in 2 patients. It is related to a particular type of gadolinium (gadodiamide) used for contrast-enhanced radiologic studies. OBSERVATIONS: Erythematous plaques, 0.5 to 2.5 cm in diameter, were pruritic in one case and asymptomatic in a second case. Findings from the histopathologic examination revealed eosinophilic, collagenous, round or ovoid bodies (sclerotic bodies) in various stages of calcification. Previously, these sclerotic bodies were thought to be pathognomonic for nephrogenic systemic fibrosis (NSF) in the setting of chronic renal disease with associated gadolinium exposure. Neither patient had NSF, while only 1 of these patients had renal disease. The patient who did not have renal disease received high doses of gadolinium. CONCLUSIONS AND RELEVANCE: Physicians should be aware that GAP can occur without NSF or renal disease and is associated with the use of radiologic dyes. Sclerotic bodies have been reported only in association with gadolinium exposure (eg, gadodiamide) either in the sclerotic skin in NSF or in GAP. |
| doi_str_mv | 10.1001/jamadermatol.2014.2660 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1663657475</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>1935472</ama_id><sourcerecordid>1663657475</sourcerecordid><originalsourceid>FETCH-LOGICAL-a277t-da7b0f581353389fc0f8abaa83c9d00f753e7c72c87edfa3041fb71605d531b93</originalsourceid><addsrcrecordid>eNpNkMlOwzAQhi0EolXpC3CocuRAyjiOl3CrSilIFXCAs-V4kVxlKXEC6tuTqKUwl5nDv4w-hGYY5hgA321VqYxtStXWxTwBnM4TxuAMjRPMRMxApOenm4kRmoawhX4EQErwJRollIiMZ3SMFmtl6sJXvivjRQi19qq1Jnor1Gdnw320iF7s92304EPrK936LxstB7lWRbSqWt_ur9CFU0Ww0-OeoI_H1fvyKd68rp-Xi02sEs7b2Cieg6MCE0r6cqfBCZUrJYjODIDjlFiueaIFt8YpAil2OccMqKEE5xmZoJtD7q6ph99aWfqgbVGoytZdkJgxwihP-6AJYgepbuoQGuvkrvGlavYSgxwIyv8E5UBQDgR74-zY0eWlNSfbL69ecH0Q9P6_0IzQlCfkB28Pd4o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1663657475</pqid></control><display><type>article</type><title>Gadolinium-Associated Plaques: A New, Distinctive Clinical Entity</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Gathings, Robert M ; Reddy, Raveena ; Santa Cruz, Daniel ; Brodell, Robert T</creator><creatorcontrib>Gathings, Robert M ; Reddy, Raveena ; Santa Cruz, Daniel ; Brodell, Robert T</creatorcontrib><description>IMPORTANCE: A new condition, gadolinium-associated plaques (GAP), is reported in 2 patients. It is related to a particular type of gadolinium (gadodiamide) used for contrast-enhanced radiologic studies. OBSERVATIONS: Erythematous plaques, 0.5 to 2.5 cm in diameter, were pruritic in one case and asymptomatic in a second case. Findings from the histopathologic examination revealed eosinophilic, collagenous, round or ovoid bodies (sclerotic bodies) in various stages of calcification. Previously, these sclerotic bodies were thought to be pathognomonic for nephrogenic systemic fibrosis (NSF) in the setting of chronic renal disease with associated gadolinium exposure. Neither patient had NSF, while only 1 of these patients had renal disease. The patient who did not have renal disease received high doses of gadolinium. CONCLUSIONS AND RELEVANCE: Physicians should be aware that GAP can occur without NSF or renal disease and is associated with the use of radiologic dyes. Sclerotic bodies have been reported only in association with gadolinium exposure (eg, gadodiamide) either in the sclerotic skin in NSF or in GAP.</description><identifier>ISSN: 2168-6068</identifier><identifier>EISSN: 2168-6084</identifier><identifier>DOI: 10.1001/jamadermatol.2014.2660</identifier><identifier>PMID: 25389795</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Aged ; Aged, 80 and over ; Calcinosis - chemically induced ; Calcinosis - pathology ; Contrast Media - administration & dosage ; Contrast Media - adverse effects ; Drug Eruptions - etiology ; Drug Eruptions - pathology ; Erythema - chemically induced ; Erythema - pathology ; Female ; Gadolinium DTPA - administration & dosage ; Gadolinium DTPA - adverse effects ; Humans ; Male</subject><ispartof>JAMA dermatology (Chicago, Ill.), 2015-03, Vol.151 (3), p.316-319</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamadermatology/articlepdf/10.1001/jamadermatol.2014.2660$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2014.2660$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,780,784,3340,27924,27925,76489,76492</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25389795$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gathings, Robert M</creatorcontrib><creatorcontrib>Reddy, Raveena</creatorcontrib><creatorcontrib>Santa Cruz, Daniel</creatorcontrib><creatorcontrib>Brodell, Robert T</creatorcontrib><title>Gadolinium-Associated Plaques: A New, Distinctive Clinical Entity</title><title>JAMA dermatology (Chicago, Ill.)</title><addtitle>JAMA Dermatol</addtitle><description>IMPORTANCE: A new condition, gadolinium-associated plaques (GAP), is reported in 2 patients. It is related to a particular type of gadolinium (gadodiamide) used for contrast-enhanced radiologic studies. OBSERVATIONS: Erythematous plaques, 0.5 to 2.5 cm in diameter, were pruritic in one case and asymptomatic in a second case. Findings from the histopathologic examination revealed eosinophilic, collagenous, round or ovoid bodies (sclerotic bodies) in various stages of calcification. Previously, these sclerotic bodies were thought to be pathognomonic for nephrogenic systemic fibrosis (NSF) in the setting of chronic renal disease with associated gadolinium exposure. Neither patient had NSF, while only 1 of these patients had renal disease. The patient who did not have renal disease received high doses of gadolinium. CONCLUSIONS AND RELEVANCE: Physicians should be aware that GAP can occur without NSF or renal disease and is associated with the use of radiologic dyes. Sclerotic bodies have been reported only in association with gadolinium exposure (eg, gadodiamide) either in the sclerotic skin in NSF or in GAP.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Calcinosis - chemically induced</subject><subject>Calcinosis - pathology</subject><subject>Contrast Media - administration & dosage</subject><subject>Contrast Media - adverse effects</subject><subject>Drug Eruptions - etiology</subject><subject>Drug Eruptions - pathology</subject><subject>Erythema - chemically induced</subject><subject>Erythema - pathology</subject><subject>Female</subject><subject>Gadolinium DTPA - administration & dosage</subject><subject>Gadolinium DTPA - adverse effects</subject><subject>Humans</subject><subject>Male</subject><issn>2168-6068</issn><issn>2168-6084</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkMlOwzAQhi0EolXpC3CocuRAyjiOl3CrSilIFXCAs-V4kVxlKXEC6tuTqKUwl5nDv4w-hGYY5hgA321VqYxtStXWxTwBnM4TxuAMjRPMRMxApOenm4kRmoawhX4EQErwJRollIiMZ3SMFmtl6sJXvivjRQi19qq1Jnor1Gdnw320iF7s92304EPrK936LxstB7lWRbSqWt_ur9CFU0Ww0-OeoI_H1fvyKd68rp-Xi02sEs7b2Cieg6MCE0r6cqfBCZUrJYjODIDjlFiueaIFt8YpAil2OccMqKEE5xmZoJtD7q6ph99aWfqgbVGoytZdkJgxwihP-6AJYgepbuoQGuvkrvGlavYSgxwIyv8E5UBQDgR74-zY0eWlNSfbL69ecH0Q9P6_0IzQlCfkB28Pd4o</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>Gathings, Robert M</creator><creator>Reddy, Raveena</creator><creator>Santa Cruz, Daniel</creator><creator>Brodell, Robert T</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150301</creationdate><title>Gadolinium-Associated Plaques: A New, Distinctive Clinical Entity</title><author>Gathings, Robert M ; Reddy, Raveena ; Santa Cruz, Daniel ; Brodell, Robert T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a277t-da7b0f581353389fc0f8abaa83c9d00f753e7c72c87edfa3041fb71605d531b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Calcinosis - chemically induced</topic><topic>Calcinosis - pathology</topic><topic>Contrast Media - administration & dosage</topic><topic>Contrast Media - adverse effects</topic><topic>Drug Eruptions - etiology</topic><topic>Drug Eruptions - pathology</topic><topic>Erythema - chemically induced</topic><topic>Erythema - pathology</topic><topic>Female</topic><topic>Gadolinium DTPA - administration & dosage</topic><topic>Gadolinium DTPA - adverse effects</topic><topic>Humans</topic><topic>Male</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gathings, Robert M</creatorcontrib><creatorcontrib>Reddy, Raveena</creatorcontrib><creatorcontrib>Santa Cruz, Daniel</creatorcontrib><creatorcontrib>Brodell, Robert T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA dermatology (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gathings, Robert M</au><au>Reddy, Raveena</au><au>Santa Cruz, Daniel</au><au>Brodell, Robert T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gadolinium-Associated Plaques: A New, Distinctive Clinical Entity</atitle><jtitle>JAMA dermatology (Chicago, Ill.)</jtitle><addtitle>JAMA Dermatol</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>151</volume><issue>3</issue><spage>316</spage><epage>319</epage><pages>316-319</pages><issn>2168-6068</issn><eissn>2168-6084</eissn><abstract>IMPORTANCE: A new condition, gadolinium-associated plaques (GAP), is reported in 2 patients. It is related to a particular type of gadolinium (gadodiamide) used for contrast-enhanced radiologic studies. OBSERVATIONS: Erythematous plaques, 0.5 to 2.5 cm in diameter, were pruritic in one case and asymptomatic in a second case. Findings from the histopathologic examination revealed eosinophilic, collagenous, round or ovoid bodies (sclerotic bodies) in various stages of calcification. Previously, these sclerotic bodies were thought to be pathognomonic for nephrogenic systemic fibrosis (NSF) in the setting of chronic renal disease with associated gadolinium exposure. Neither patient had NSF, while only 1 of these patients had renal disease. The patient who did not have renal disease received high doses of gadolinium. CONCLUSIONS AND RELEVANCE: Physicians should be aware that GAP can occur without NSF or renal disease and is associated with the use of radiologic dyes. Sclerotic bodies have been reported only in association with gadolinium exposure (eg, gadodiamide) either in the sclerotic skin in NSF or in GAP.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>25389795</pmid><doi>10.1001/jamadermatol.2014.2660</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-6068 |
| ispartof | JAMA dermatology (Chicago, Ill.), 2015-03, Vol.151 (3), p.316-319 |
| issn | 2168-6068 2168-6084 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1663657475 |
| source | MEDLINE; American Medical Association Journals |
| subjects | Aged Aged, 80 and over Calcinosis - chemically induced Calcinosis - pathology Contrast Media - administration & dosage Contrast Media - adverse effects Drug Eruptions - etiology Drug Eruptions - pathology Erythema - chemically induced Erythema - pathology Female Gadolinium DTPA - administration & dosage Gadolinium DTPA - adverse effects Humans Male |
| title | Gadolinium-Associated Plaques: A New, Distinctive Clinical Entity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T08%3A59%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gadolinium-Associated%20Plaques:%20A%20New,%20Distinctive%20Clinical%20Entity&rft.jtitle=JAMA%20dermatology%20(Chicago,%20Ill.)&rft.au=Gathings,%20Robert%20M&rft.date=2015-03-01&rft.volume=151&rft.issue=3&rft.spage=316&rft.epage=319&rft.pages=316-319&rft.issn=2168-6068&rft.eissn=2168-6084&rft_id=info:doi/10.1001/jamadermatol.2014.2660&rft_dat=%3Cproquest_cross%3E1663657475%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1663657475&rft_id=info:pmid/25389795&rft_ama_id=1935472&rfr_iscdi=true |